How could the newly defined reference range of 20-40 ng/mL for olanzapine impact the precision of schizophrenia treatment?
In an extensive review to refine the therapeutic reference range for olanzapine in the treatment of schizophrenia, this study investigated the association between blood olanzapine levels, clinical effects, and dopamine D2-receptor occupancy. Through a systematic search of various databases and a detailed analysis of 34 qualitative and 13 quantitative studies, the research pinpoints the optimal concentration levels for both oral and long-acting injectable (LAI) formulations.
- Objective: Revising the therapeutic reference range for olanzapine in relation to clinical outcomes and D2-receptor occupancy
- Sources: MEDLINE (PubMed), Web of Science, PsycINFO, Cochrane Library (March to December 2021)
- Selection: 2,824 articles identified; 34 for qualitative synthesis, 13 for quantitative analysis
- Language and Exclusion: Only English and German studies; non-human data excluded
- Review Protocol: Following previously published protocol and PRISMA guidelines
- Relationship between blood olanzapine level and efficacy/side effects considered low (Level C)
- Therapeutic thresholds: around 20 ng/mL for olanzapine 12 hours post-dose
- Optimal drug efficacy: 65%–80% D2-receptor occupancy between 17 and 44 ng/mL
- Side effects such as weight gain may occur at therapeutic levels
- Suggested therapeutic reference range: 20–40 ng/mL for olanzapine oral and LAI formulations
- In this range, optimal treatment for schizophrenia spectrum disorders expected
- Higher plasma concentrations generally well tolerated, dose reduction not necessarily required
Psychiatry Latest Posts
- 3 AI Essentials: Thriving in Behavioral Healthcare
- Slight Symptom Gains but More Dropouts with Unlicensed Stimulant Doses in ADHD
- What is Shadow Work, a Not-so-new Mental Health Tactic Trending on TikTok?
- MDD Symptom Improvements with Zuranolone Extend to Daily Lives, Responders Report
Did You Know?
Schizophrenia affects approximately 1% of the global population, making it one of the leading causes of disability.